Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 6
2003 8
2004 8
2005 18
2006 14
2007 15
2008 6
2009 14
2010 11
2011 17
2012 20
2013 8
2014 16
2015 18
2016 16
2017 12
2018 22
2019 12
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

238 results
Results by year
Filters applied: . Clear all
Page 1
Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival.
Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, Weston R, Jayatilleke KM, Schloegel J, Talbo G, Casey JL, Levina V, Wong WW, Dillon H, Sahay T, Hoogenraad J, Anderton H, Hall C, Schneider P, Tanzer M, Foley M, Scott AM, Gregorevic P, Liu SY, Burkly LC, Lynch GS, Silke J, Hoogenraad NJ. Johnston AJ, et al. Among authors: Scott AM. Cell. 2015 Sep 10;162(6):1365-78. doi: 10.1016/j.cell.2015.08.031. Cell. 2015. PMID: 26359988 Free article.
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.
Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM. Roach PJ, et al. Among authors: Scott AM. J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23. J Nucl Med. 2018. PMID: 28646014 Free article. Clinical Trial.
Evolution of anti-HER2 therapies for cancer treatment.
Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM. Parakh S, et al. Among authors: Scott AM. Cancer Treat Rev. 2017 Sep;59:1-21. doi: 10.1016/j.ctrv.2017.06.005. Epub 2017 Jul 6. Cancer Treat Rev. 2017. PMID: 28715775 Review.
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB. Phillips AC, et al. Among authors: Scott AM. Mol Cancer Ther. 2018 Apr;17(4):795-805. doi: 10.1158/1535-7163.MCT-17-0710. Epub 2018 Feb 26. Mol Cancer Ther. 2018. PMID: 29483208 Free article.
Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM. Binder ZA, et al. Among authors: Scott AM. Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006. Cancer Cell. 2018. PMID: 29990498 Free PMC article.
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.
Jahani-Asl A, Yin H, Soleimani VD, Haque T, Luchman HA, Chang NC, Sincennes MC, Puram SV, Scott AM, Lorimer IA, Perkins TJ, Ligon KL, Weiss S, Rudnicki MA, Bonni A. Jahani-Asl A, et al. Among authors: Scott AM. Nat Neurosci. 2016 Jun;19(6):798-806. doi: 10.1038/nn.4295. Epub 2016 Apr 25. Nat Neurosci. 2016. PMID: 27110918 Free PMC article.
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.
Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Lehn S, Sjölund J, Reid S, Larsson C, Eriksson P, Anderberg C, Cortez E, Saal LH, Orsmark-Pietras C, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K. Roswall P, et al. Among authors: Scott AM. Nat Med. 2018 May;24(4):463-473. doi: 10.1038/nm.4494. Epub 2018 Mar 12. Nat Med. 2018. PMID: 29529015 Free PMC article.
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. Gan HK, et al. Among authors: Scott AM. Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202. Neuro Oncol. 2018. PMID: 29077941 Free PMC article. Clinical Trial.
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Lassman AB, et al. Among authors: Scott AM. Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091. Neuro Oncol. 2019. PMID: 29982805 Free PMC article. Clinical Trial.
Antibody-Drug Conjugates for Cancer Therapy.
Parslow AC, Parakh S, Lee FT, Gan HK, Scott AM. Parslow AC, et al. Among authors: Scott AM. Biomedicines. 2016 Jul 11;4(3):14. doi: 10.3390/biomedicines4030014. Biomedicines. 2016. PMID: 28536381 Free PMC article. Review.
238 results
Jump to page
Feedback